Bladder cancer
Conditions
Interventions
Gold Standard:Cystoscope and related pathological diagnosis.
Mutation?Methylation?Copy 
Variation.
Sponsors
Department of Urology, The Third Xiangya Hospital of Central South University
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Patients were pathologically diagnosed with urothelial carcinoma and required repeated transurethral resection, aged >= 18 years; 2.The clinical samples of each clinical trial object should be fresh and sufficient (Urine sample volume should be at least 40 ml); 3.All samples are from outpatient or inpatient specimens of clinical hospitals, and all samples must have clinical diagnosis or pathological diagnosis; 4.All samples should have corresponding basic clinical information, including sample ID number (outpatient number, medical record number, contact information and hospital number), gender, age, smoking history, chemical exposure history, family history of bladder cancer and clinical diagnosis information.
Exclusion criteria
Exclusion criteria: 1. Sample number (medical record number or hospital number, etc.), gender, age, clinical diagnosis and other information missing; 2. Samples are not fresh; 3. Samples are insufficient in quantity or abnormal in quality (Urine sample volume < 40 ml); 4. The concentration(5ng/µL of urine sample is not satisfactory; 5. The appearance color of urine samples was inconsistent or may be confused from 4 tubes.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinalysis;DNA Point Mutation;Methylation;Copy Number Variation; | — |
Countries
China
Contacts
Public ContactLong Wang
Department of Urology, Xiangya Third Hospital of Central South University
Outcome results
None listed